Biocryst Pharmaceuticals Inc (NASDAQ: BCRX) on Friday, soared 5.24% from the previous trading day, before settling in for the closing price of $8.01. Within the past 52 weeks, BCRX’s price has moved between $4.03 and $8.88.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 190.00% over the last five years. The company achieved an average annual earnings per share of 68.81%. With a float of $195.87 million, this company’s outstanding shares have now reached $205.77 million.
The firm has a total of 536 workers. Let’s measure their productivity. In terms of profitability, gross margin is 98.3%, operating margin of -15.75%, and the pretax margin is -38.33%.
Biocryst Pharmaceuticals Inc (BCRX) Breakdown of a Key Holders of the stock
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Biocryst Pharmaceuticals Inc is 5.32%, while institutional ownership is 82.49%. The most recent insider transaction that took place on Jun 24 ’24, was worth 54,352. In this transaction Director of this company sold 8,600 shares at a rate of $6.32, taking the stock ownership to the 27,831 shares. Before that another transaction happened on Jun 17 ’24, when Company’s Director sold 4,689 for $6.00, making the entire transaction worth $28,134. This insider now owns 27,742 shares in total.
Biocryst Pharmaceuticals Inc (BCRX) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around 68.81% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 44.80% during the next five years compared to -3.73% drop over the previous five years of trading.
Biocryst Pharmaceuticals Inc (NASDAQ: BCRX) Trading Performance Indicators
Biocryst Pharmaceuticals Inc (BCRX) is currently performing well based on its current performance indicators. A quick ratio of 2.78 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 4.80.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.73, a number that is poised to hit -0.07 in the next quarter and is forecasted to reach -0.11 in one year’s time.
Technical Analysis of Biocryst Pharmaceuticals Inc (BCRX)
Analysing the last 5-days average volume posted by the [Biocryst Pharmaceuticals Inc, BCRX], we can find that recorded value of 1.78 million was lower than the volume posted last year of 2.94 million. As of the previous 9 days, the stock’s Stochastic %D was 86.55%. Additionally, its Average True Range was 0.31.
During the past 100 days, Biocryst Pharmaceuticals Inc’s (BCRX) raw stochastic average was set at 84.80%, which indicates a significant decrease from 99.05% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 42.22% in the past 14 days, which was lower than the 45.06% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $7.84, while its 200-day Moving Average is $6.42. Now, the first resistance to watch is $8.58. This is followed by the second major resistance level at $8.73. The third major resistance level sits at $9.02. If the price goes on to break the first support level at $8.14, it is likely to go to the next support level at $7.85. Now, if the price goes above the second support level, the third support stands at $7.70.
Biocryst Pharmaceuticals Inc (NASDAQ: BCRX) Key Stats
Market capitalization of the company is 1.84 billion based on 206,886K outstanding shares. Right now, sales total 331,410 K and income totals -226,540 K. The company made 109,330 K in profit during its latest quarter, and -12,670 K in sales during its previous quarter.
